Saturday, June 29, 2024
23andMe Holding Co. (Nasdaq: ME) and Nightingale Health Plc have announced a strategic collaboration to pilot Nightingale Health’s clinically-validated blood metabolomics panel with a group of 23andMe members.
Nightingale’s Remote Health Check assesses various biomarkers like cholesterols, apolipoproteins, and omega-3 fatty acids from a single blood sample. These biomarkers are clinically associated with diseases and can guide personalized lifestyle interventions such as diet and exercise. This pilot aims to improve the accessibility and efficiency of blood testing.
Up to 5,000 23andMe+ Premium and Total Health members will have the opportunity to participate in Nightingale’s Remote Health Check at no cost. The pilot will gather feedback on blood testing, at-home sample collection, and the integration of this data with 23andMe’s existing personal genetics products.
Both companies aim to empower individuals by identifying health risks early and preventing diseases through proactive testing and personalized interventions. This collaboration combines their technologies to offer a comprehensive health assessment and continuous progress tracking toward health goals.
23andMe, is excited about the potential of Nightingale Health’s biomarker testing capabilities to improve customer health outcomes. Teemu Suna, CEO and Founder of Nightingale Health, emphasizes the partnership’s role in expanding access to consumer health services through innovative blood testing technologies.
Source: globenewswire.com
